Chinese biotech company HitGen Inc (688222.SH) said on Saturday that it has extended the previous drug discovery research collaboration to identify small molecule leads against targets specified by Morphic Therapeutic.
Pursuant to the extended agreement, HitGen will use its DNA-encoded library (DEL) technology platform based on the design, synthesis and interrogation and selection to discover ligands for targets of interest to Morphic.
In conjunction with the collaboration, Morphic will pay an assignment fee to HitGen in exchange for exclusive development and commercialization rights to compounds that achieve the criteria of the collaboration.
Additionally, HitGen's industry-leading DNA-encoded library (DEL) technology platform includes over 400bn encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds.
AFYREN ingredient enables global launch of natural propionic acid skincare product
Fresenius acquires remaining stake in mAbxience
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Merck reports positive Phase 2b results for tulisokibart in hidradenitis suppurativa
Genentech's fenebrutinib receives FDA priority review for multiple sclerosis
Takeda reports positive Phase 3 psoriasis results for zasocitinib versus deucravacitinib
Oxurion in talks to acquire Eclevar's MedTech CRO business and assets
DBV Technologies submits FDA application for VIASKIN Peanut Patch in children
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Viking Therapeutics closes offerings of common stock and convertible senior notes
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
4basebio announces Phase I cell therapy programme partnership with TriLink